Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - TargeGen

  • Sanofi Presents Encouraging Phase III Data for Myelofibrosis...
    Sanofi acquired the drug candidate in 2010 when it snapped up small molecule drug development firm TargeGen. Sanofi today announced that its Phase III JAKARTA study evaluating its ...
    5-17-2013
  • People in the News
    ... Noronha held leadership roles at Alcon Laboratories, now part of Novartis. He also filled positions at TargeGen, now acquired by Sanofi-Aventis. Christine E. Garnett is now ...
    10-15-2012
  • Sanofi-Aventis Acquires TargeGen and Inks Partnership with JDRF
    Sanofi-Aventis is taking over TargeGen, a developer of small molecule kinase inhibitors. ... The ultimate purchase price for TargeGen will depend on the achievement of ...
    7-1-2010
  • China Looks to Accelerate Globalization
    ... WuXi also works with smaller biotechnology companies, for example, testing small molecule compounds for cardiovascular disease for TargeGen (www.targegen.com). Finally, one of the ...
    5-1-2007
  • Combating Ocular Disease
    ... be explored for inhibiting cell proliferation and neovascularization that comes with wet AMD," says Richard M. Soll, vp of research and development at TargeGen (www.targen.com). ...
    4-1-2007
  • Cell Signaling Pathway Analysis
    ... Together, theses pathways paint a comprehensive picture of mechanism of action of their antibody therapy. P13-kinase Isoform Specificity TargeGen (www.targen.com) is fo-cused on ...
    3-15-2007
  • Small Molecule Drugs
    New Paradigm for Development Peter Ulrich, Ph.D., is cofounder and CEO of TargeGen (www.targegen.com), a company that specializes in therapeutics against vascular leakage, a ...
    11-1-2006

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll